AYTU Aytu BioPharma
- 2.9043
- +0.0643+2.26%
Aytu BioPharma News
Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now
Aytu BioPharma Second Quarter 2024 Earnings: Beats Expectations
Earnings Call: Aytu BioPharma Achieves First Positive Operating Income
Earnings Call Summary | Aytu BioPharma(AYTU.US) Q2 2024 Earnings Conference
The following is a summary of the Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript:Financial Performance:Aytu BioPharma achieved $5.1 million in adjusted EBITDA, up from the previous year'
Aytu BioPharma Q2 2024 GAAP EPS $(0.04) Beats $(0.25) Estimate, Sales $22.93M Beat $21.75M Estimate
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.25) by 84 percent. The company reported quarterly sales of $22.93 million
Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, Vs. Street Est of $21.75M
04:07 PM EST, 02/14/2024 (MT Newswires) -- Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
Q2 2024 operating income of $2.4 millionQ2 2024 net loss of $0.2 million and adjusted EBITDA1 of $5.1 millionQ2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted E
Earnings Scheduled For February 14, 2024
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is projected to report quarterly earnings at $1.65 per share on revenue of $24.62 billion. • CAE (NYSE:CAE) is estimated to report quarterl
Notable Earnings After Wednesday's Close
Earnings Preview: Aytu BioPharma
Aytu BioPharma (NASDAQ:AYTU) is set to give its latest quarterly earnings report on Wednesday, 2024-02-14. Here's what investors need to know before the announcement.Analysts estimate that Aytu BioPha
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024
DENVER, CO / ACCESSWIRE / February 7, 2024 / Aytu BioPharma, Inc. , a pharmaceutical company focused on commercializing novel therapeutics, will report its
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
When Will Aytu BioPharma, Inc. (NASDAQ:AYTU) Become Profitable?
Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023
Webcasted presentation to take place at 1:10pm ETDENVER, CO / ACCESSWIRE / November 30, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercia
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersTelesis Bio (NASDAQ:TBIO) shares increased by 32.5% to $0.53 during Wednesday's after-market session. The company's market cap stands at $15.8 million. Femasys (NASDAQ:FEMY) shares rose 19.28%
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersHeron Therapeutics (NASDAQ:HRTX) stock moved upwards by 63.0% to $0.88 during Wednesday's regular session. As of 12:31 EST, Heron Therapeutics's stock is trading at a volume of 15.8 million, wh
Top 10 Stocks Under $10, as Ranked by SA's Quant Ratings
Aytu BioScience GAAP EPS of -$1.48 Misses by $1.44, Revenue of $22.1M Misses by $5.63M
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q1 Revenue $22.1M, Vs. Street Est of $27.7M
04:23 PM EST, 11/14/2023 (MT Newswires) -- Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q1 Revenue $22.1M, vs. Street Est of $27.7M
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
Q1 2024 Adjusted EBITDA of $2.2 millionRx Segment net revenue of $17.8 million and Adjusted EBITDA of $2.4 million in Q1 2024Q1 2024 ADHD net revenue up 31% compared to Q1 2023$20.0 million cash balan
Analysis
Price Target
No Data
